About Retinalamin
Polypeptide bioregulator from bovine retina; normalizes retinal pigment epithelial and photoreceptor cell function; reduces oxidative damage in retinal tissue
Retinalamin is a polypeptide bioregulator preparation derived from retinal tissue, classified as a Khavinson-class agent investigated for neuroprotective and anti-aging effects in photoreceptors and retinal ganglion cells, proposed to support visual function by modulating gene expression and cellular homeostasis in aging retinal tissue. Like other Khavinson bioregulator preparations, retinalamin is proposed to exert tissue-specific regulatory effects through intracellular transport of ultrashort active peptide components via amino acid carrier mechanisms, modulating transcriptional activity in retinal pigment epithelium and photoreceptor cells under degenerative or age-related stress conditions. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport mechanisms via POT and LAT carriers and neuroepigenetic regulatory actions in aging neural tissue, providing the class-level mechanistic framework within which retinalamin's retinal effects are proposed. Retinalamin has no FDA approval; it is used as a clinical preparation in Russia and Eastern Europe for degenerative retinal conditions, and its evidence base derives from Russian-origin preclinical and observational studies that have not been independently replicated in Western-indexed clinical literature.
Retinalamin Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Russian retinal peptide bioregulator (Khavinson Institute). Used in Russia for age-related retinal degeneration. Not FDA-approved. Not available in US except as research chemical.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 moderate
2 Reviews
Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium
International Journal of Molecular Sciences · 2022
This review documents the cellular uptake mechanisms of short regulatory peptides including retinalamin via POT and LAT transporter systems, demonstrating nuclear translocation and chromatin binding activity relevant to retinalamin's transcriptional regulatory function in retinal tissue cells.
Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies
International Journal of Molecular Sciences · 2022
This review examines the bioavailability and biological activities of short peptides including retinalamin and related retinal peptide regulators, providing mechanistic context for their documented effects on retinal tissue protection and age-related degenerative changes in the eye.
Retinalamin Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Retinalamin — Providers & Availability
1 providerClinics
1 providerStay updated on verified Retinalamin providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Retinalamin
Retinalamin is a polypeptide bioregulator preparation derived from retinal tissue, classified as a Khavinson-class agent investigated for neuroprotective and anti-aging effects in photoreceptors and retinal ganglion cells, proposed to support visual function by modulating gene expression and cellular homeostasis in aging retinal tissue. Like other Khavinson bioregulator preparations, retinalamin is proposed to exert tissue-specific regulatory effects through intracellular transport of ultrashort active peptide components via amino acid carrier mechanisms, modulating transcriptional activity in retinal pigment epithelium and photoreceptor cells under degenerative or age-related stress conditions.
retinal cell protection, visual function restoration, macular degeneration support, anti-aging (eyes).
Research on Retinalamin primarily documents effects related to retinal cell protection and visual function restoration and macular degeneration support and anti-aging (eyes). These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Retinalamin include bovine protein allergy. This is educational information only — consult a qualified healthcare professional before use.
1 provider in the directory currently offers Retinalamin.
This review documents the cellular uptake mechanisms of short regulatory peptides including retinalamin via POT and LAT transporter systems, demonstrating nuclear translocation and chromatin binding activity relevant to retinalamin's transcriptional regulatory function in retinal tissue cells.